Meeting Minutes: Drug Formulary Committee

Date & Time: July 16, 2019; 5:30-9 PM
Minutes prepared by: Hind Douiki and Dave Hoang
Location: Elmer Andersen Building, Room 2370, 540 Cedar Street, St. Paul, MN 55101

Attendance

- Members in attendance: Margaret Artz, RPh., PhD.; Al Heaton, RPh.; Kyle Lehenbauer, MD.; Kathryn Lombardo, MD.; Stacey Ness, PharmD.; James Phillips, MD.; Kelly Ruby, PharmD.; Michael Sprehe, MD.; Stuart Williams, J.D.; Mary Mescher Benbenek, APRN, PhD.; Ramona Powell, PharmD.
- Member absent: Monica Brands, RPh.
- DHS staff present: Dave Hoang, PharmD., MBA; Sharon Feinstein-Rosenblum, PharmD; Mary Beth Reinke, Pharm.D., MSA.
- Others in attendance: Hind Douiki, PharmD.; Ariane Casey, PharmD.

Report of the Chair

- Dr. Ness presided over the meeting.

Approval of Minutes

- Minutes from the June 2019 meeting were reviewed and approved.

DHS Housekeeping

- Ethics training was provided to the DFC committee members by Nikki Thompson, DHS Ethics Officer. Training topics include conflicts of interest and MN Open Meeting Law

Old Business

Existing Specialty Drugs for Continued PA

- The committee discussed Hepatitis C Direct Acting Antivirals and recommended to the department by a unanimous vote that Hepatitis C Direct Acting Antivirals remain on PA, with approval to the proposed criteria 1. Dave will look into the correct Fibroscan score for severe liver disease.
- The committee also discussed Hepatitis C Direct Acting Antivirals PA criteria 2 and recommended to the department by a unanimous vote to approve the proposed criteria 2, with removal of the words “history of” in the first sentence.
New Business

Existing Specialty Drugs for Continued PA

Transgender Health Medications

A. Testosterone: The committee discussed testosterone and recommended to the department by a unanimous vote that testosterone remain on PA, with the following revisions to the criteria:
   1. Addition of the word “have” after “must” in the third bullet.
   2. Addition of the following language: “If the patient is 18 years of age or older,” to the second sub-bullet of the fourth bullet.
   3. Deletion of the words “and give informed consent” from the second sub-bullet of the fourth bullet.

B. Histrelin acetate and Leuprolide: The committee discussed Histrelin acetate and Leuprolide and recommended to the department by a unanimous vote that Histrelin acetate and Leuprolide remain on PA, with the following revisions to the criteria:
   1. Addition of “If the patient is 18 years of age or older,” to the second sub-bullet of the third bullet.
   2. Deletion of the words “and give informed consent” from the second sub-bullet of the third bullet.

The committee approved a motion to move the “Preferred Drug List Review” agenda item to the end.

New Specialty Drugs for Continued PA

- The committee discussed Libtayo and recommended to the department by a unanimous vote that Libtayo remain on PA.

- The committee discussed Bryhali and recommended to the department by a unanimous vote that Bryhali remain on PA, with an additional criterion of trial and failure of one other high potency corticosteroid.

- The committee discussed Diacomit and recommended to the department by a unanimous vote that Diacomit remain on PA, with the addition of the following language to the first bullet of the Quantity Limits criteria: “If the exact dosage is not achievable given the available strengths, round to the nearest possible dosage, which is usually within 50 mg to 150 mg of the recommended 50 mg/kg/day.”

- The committee discussed Bevyxxa and recommended to the department by a unanimous vote that Bevyxxa remain on PA, with the following revisions to the criteria:
   1. Addition of the following criterion to the Approval Criteria: “Patient has tried and failed one preferred agent in the same drug class”
   2. Addition of the following criterion to the Denial Criteria: “Patient has prosthetic heart valve”
• The committee discussed Mayzent and recommended to the department by a unanimous vote that Mayzent remain on PA.

• The committee discussed Mavenclad and recommended to the department by a unanimous vote that Mavenclad remain on PA, with the following revisions to the criteria:
  1. Addition of the word “active” before “secondary progressive disease” in the third bullet of the Initial Approval Criteria.
  2. Deletion of the words “with relapses” in the third bullet of the Initial Approval Criteria.

Preferred Drug List Review

1. Anticonvulsant
   a. Diacomit: The committee discussed Diacomit and recommended to the department by a unanimous vote that Diacomit be nonpreferred.

2. Multiple Sclerosis Agents
   a. Mayzent: The committee discussed Mayzent and recommended to the department by a unanimous vote that Mayzent be nonpreferred.
   b. Mavenclad: The committee discussed Mavenclad and recommended to the department by a unanimous vote that Mavenclad be nonpreferred.

Dave provided to the DFC committee members the definition of specialty pharmacy products, per the Minnesota Statute 256B.0625 subd. e (f).

Adjournment

• The meeting was adjourned at approximately 9:06 PM Central Time.